Dataset Information


Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.

ABSTRACT: Cystic fibrosis (CF) is an autosomal recessive inherited life-threatening disorder that causes severe damage to the lungs and the digestive system. In Palestine, mutations in the Cystic Fibrosis Transmembrane Conductance Regulator gene (CFTR) that contributes to the clinical presentation of CF are ill defined. A cohort of thirty three clinically diagnosed CF patients from twenty one different Palestinian families residing in the central and southern part of Palestine were incorporated in this study. Sweat chloride testing was performed using the Sweat Chek Conductivity Analyzer (ELITECH Group, France) to confirm the clinical diagnosis of CF. In addition, nucleic acid from the patients' blood samples was extracted and the CFTR mutation profiles were assessed by direct sequencing of the CFTR 27 exons and the intron-exon boundaries. For patient's DNA samples where no homozygous or two heterozygous CFTR mutations were identified by exon sequencing, DNA samples were tested for deletions or duplications using SALSA MLPA probemix P091-D1 CFTR assay. Sweat chloride testing confirmed the clinical diagnosis of CF in those patients. All patients had NaCl conductivity >60 mmol/l. In addition, nine different CFTR mutations were identified in all 21 different families evaluated. These mutations were c.1393-1G>A, F508del, W1282X, G85E, c.313delA, N1303K, deletion exons 17a-17b-18, deletion exons 17a-17b and Q1100P. c.1393-1G>A was shown to be the most frequent occurring mutation among tested families. We have profiled the underling mutations in the CFTR gene of a cohort of 21 different families affected by CF. Unlike other studies from the Arab countries where F508del was reported to be the most common mutation, in southern/central Palestine, the c.1393-1G>A appeared to be the most common. Further studies are needed per sample size and geographic distribution to account for other possible CFTR genetic alterations and their frequencies. Genotype/phenotype assessments are also recommended and finally carrier frequency should be ascertained.


PROVIDER: S-EPMC4514804 | BioStudies | 2015-01-01

SECONDARY ACCESSION(S): 10.1371/journal.pone.0133890

REPOSITORIES: biostudies

Similar Datasets

2015-01-01 | S-EPMC4321085 | BioStudies
2016-01-01 | S-EPMC4983674 | BioStudies
2017-01-01 | S-EPMC5662556 | BioStudies
2014-01-01 | S-EPMC3919757 | BioStudies
2016-01-01 | S-EPMC5121184 | BioStudies
2013-01-01 | S-EPMC3608608 | BioStudies
2014-01-01 | S-EPMC4227699 | BioStudies
2020-01-01 | S-EPMC7177453 | BioStudies
2014-01-01 | S-EPMC4502695 | BioStudies
2014-01-01 | S-EPMC4023213 | BioStudies